{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:27:53Z","timestamp":1788805673329,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:00:00Z","timestamp":1705795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ctro.2024.100733","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T13:39:13Z","timestamp":1706449153000},"page":"100733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-5839","authenticated-orcid":false,"given":"A.","family":"Gomez-Iturriaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7704-4560","authenticated-orcid":false,"given":"D.","family":"B\u00fcchser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-0507","authenticated-orcid":false,"given":"F.","family":"Lopez-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-4723","authenticated-orcid":false,"given":"X.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2024.100733_b0005","first-page":"1","article-title":"Combining androgen deprivation and radiation therapy in the treatment of localised prostate cancer: Summary of level 1 evidence and current gaps in knowledge","volume":"37","author":"Baude","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2024.100733_b0010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(22)00190-5","article-title":"High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01\/05): 10-year results of a phase 3 randomised, controlled trial","volume":"23","author":"Zapatero","year":"2022","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.ctro.2024.100733_b0015","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctro.2024.100733_b0020","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ctro.2024.100733_b0025","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.2015.8577","article-title":"Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"314","author":"D\u2019Amico","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ctro.2024.100733_b0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2024.100733_b0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(21)00406-X","article-title":"Should brachytherapy be added to external beam radiotherapy for prostate cancer?","volume":"23","author":"Gomez-Iturriaga","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2024.100733_b0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2024.100733_b0045","doi-asserted-by":"crossref","first-page":"e216871","DOI":"10.1001\/jamaoncol.2021.6871","article-title":"Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer: A patient-level data analysis of 3 cohorts","volume":"8","author":"Kishan","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2024.100733_b0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.brachy.2016.11.017","article-title":"American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review","volume":"16","author":"Keyes","year":"2017","journal-title":"Brachytherapy"},{"issue":"4","key":"10.1016\/j.ctro.2024.100733_b0055","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.adro.2019.07.007","article-title":"A phase I\/II trial of fairly brief androgen suppression and stereotactic radiation therapy for high-risk prostate cancer (FASTR-2): preliminary results and toxicity analysis","volume":"4","author":"Callan","year":"2019","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2024.100733_b0060","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase 1\u20132 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): early toxicity and quality of Life","volume":"102","author":"Musunuru","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2024.100733_b0065","doi-asserted-by":"crossref","first-page":"e034623","DOI":"10.1136\/bmjopen-2019-034623","article-title":"Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL)","volume":"10","author":"Murthy","year":"2020","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.ctro.2024.100733_b0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"issue":"9","key":"10.1016\/j.ctro.2024.100733_b0075","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1002\/cam4.2966","article-title":"Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results","volume":"9","author":"Zilli","year":"2020","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.ctro.2024.100733_b0080","doi-asserted-by":"crossref","first-page":"e1920471","DOI":"10.1001\/jamanetworkopen.2019.20471","article-title":"Trends in the use of stereotactic body radiotherapy for treatment of prostate cancer in the United States","volume":"3","author":"Mahase","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6_suppl","key":"10.1016\/j.ctro.2024.100733_b0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.370","article-title":"Utilization of androgen deprivation therapy (ADT) and stereotactic body radiation therapy (SBRT) for localized prostate cancer (PC) in the United States (US)","volume":"38","author":"Royce","year":"2020","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.ctro.2024.100733_b0090","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13014-020-01658-5","article-title":"Stereotactic body radiotherapy versus conventional\/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer","volume":"15","author":"Patel","year":"2020","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2024.100733_b0095","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijrobp.2021.01.016","article-title":"Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) Consortium: analysis of 344 prospectively treated patients","volume":"110","author":"van Dams","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2024.100733_b0100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2024.100733_b0105","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10196","key":"10.1016\/j.ctro.2024.100733_b0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctro.2024.100733_b0115","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2024.100733_b0120","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ctro.2024.100733_b0125","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.22.00970","article-title":"Sequencing of androgen-deprivation therapy of short duration with radiotherapy for nonmetastatic prostate cancer (SANDSTORM): A pooled analysis of 12 randomized trials","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2024.100733_b0130","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.brachy.2016.07.001","article-title":"Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer","volume":"15","author":"Chen","year":"2016","journal-title":"Brachytherapy"},{"issue":"3","key":"10.1016\/j.ctro.2024.100733_b0135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.brachy.2019.01.016","article-title":"Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer","volume":"18","author":"Mohiuddin","year":"2019","journal-title":"Brachytherapy"},{"issue":"7","key":"10.1016\/j.ctro.2024.100733_b0140","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/jjco\/hyn056","article-title":"Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone","volume":"38","author":"Fang","year":"2008","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2024.100733_b0145","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/j.ijrobp.2011.08.002","article-title":"External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome","volume":"82","author":"Mart\u00ednez-Monge","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"10.1016\/j.ctro.2024.100733_b0150","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2008.20.3992","article-title":"Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease","volume":"27","author":"D\u2019Amico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2024.100733_b0155","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.2005.06.154","article-title":"Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate","volume":"23","author":"Sathya","year":"2005","journal-title":"J Clin Oncol"},{"issue":"154","key":"10.1016\/j.ctro.2024.100733_b0160","first-page":"214","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results","volume":"2","author":"Hoskin","year":"2020","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2024.100733_b0165","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2024.100733_b0170","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","volume":"20","author":"Denham","year":"2019","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ctro.2024.100733_b0175","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctro.2024.100733_b0180","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/1471-2407-10-572","article-title":"Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial","volume":"21","author":"Miki","year":"2010","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.ctro.2024.100733_b0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1471-2407-12-110","article-title":"Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial","volume":"22","author":"Konaka","year":"2012","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ctro.2024.100733_b0190","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2017.74.2940","article-title":"Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer","volume":"36","author":"Spratt","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2024.100733_b0195","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","article-title":"Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG\/RTOG 9601 randomized clinical trial","volume":"7","author":"Feng","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10231","key":"10.1016\/j.ctro.2024.100733_b0200","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ctro.2024.100733_b0205","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ctro.2024.100733_b0210","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2024.100733_b0215","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10323","key":"10.1016\/j.ctro.2024.100733_b0220","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ctro.2024.100733_b0225","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ctro.2024.100733_b0230","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824000107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824000107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T02:42:07Z","timestamp":1742179327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630824000107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":46,"alternative-id":["S2405630824000107"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100733","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100733"}}